Overdiagnosis of Breast Cancer at Screening is Clinically Insignificant

Academic Radiology

Volumn 22, Issue 8, 2015, Pages 961-966

  Feig, Stephen A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer screening; Overdiagnosis; Screening mammography

Indexed keywords

AUTOPSY; BREAST CANCER; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FOLLOW UP; GROWTH RATE; HUMAN; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; TREND STUDY; BREAST NEOPLASMS; EARLY CANCER DIAGNOSIS; FEMALE; HEALTH SERVICE; META ANALYSIS; PREVALENCE; PREVENTION AND CONTROL; RADIOGRAPHY; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; TRENDS; UTILIZATION; WOMEN'S HEALTH;

BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MAMMOGRAPHY; MEDICAL OVERUSE; PREVALENCE; RISK ASSESSMENT; WOMEN'S HEALTH;

EID: 84937977918     PISSN: 10766332     EISSN: 18784046     Source Type: Journal    
DOI: 10.1016/j.acra.2015.01.020     Document Type: Review

References (44)

1. Tabar L., Vitak B., Chen T.H.H., et al. Swedish Two-County Trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology 2011, 260:658-663.
2. Broeders M., Moss S., Nystrom L., et al. The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. J Med Screen 2012, 19(suppl 1):14-25.
3. Feig S.A. Digital breast tomosynthesis-the road ahead (invited commentary). Radiographics 2014, 34:E103.
4. Feig S.A. Pitfalls in accurate estimation of overdiagnosis: implication for screening policy and compliance. Breast Cancer Res 2013, 15:105.
5. Duffy S.W., Parmar D. Overdiagnosis in breast cancer screening: the importance of length of observation period and lead time. Breast Cancer Res 2013, 15:R41.
6. Puliti D., Duffy S.W., Miccinesi G., et al. Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen 2012, 19:42-56.
7. Bleyer A., Welch H.G. Effect of three decades of screening mammography on breast cancer incidence. N Engl J Med 2012, 367:1998-2005.
8. Seidman H., Gelb S.K., Silverberg E., et al. Survival experience in The Breast Cancer Detection Demonstration Project. CA Cancer J Clin 1987, 37:258-290.
9. Garfinkel L., Boring C.C., Heath C.W. Changing trends: an overview of breast cancer incidence and mortality. Cancer 1994, 79(suppl):222-227.
10. Kopans D.B. The New England Journal of Medicine article suggesting overdiagnosis from mammography screening is scientifically incorrect and should be withdrawn. J Am Coll Radiol 2013, 10:317-319.
11. Yen A.M.F., Duffy S.W., Chen T.H.H., et al. Long-term incidence of breast cancer by trial arm in one county of the Swedish Two County Trial of mammography screening. Cancer 2012, 118:5728-5732.
12. Esserman L., Shieh Y., Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA 2009, 302:1685-1692.
13. Cancer prevention and early detection facts and figures 2009 2009, American Cancer Society, American Cancer, Atlanta GA.
14. Feig S.A. Methods to identify benefit from mammographic screening of women aged 40-49 years. Radiology 1996, 201:309-316.
15. Morrison A.S. Screening in chronic disease 1992, Oxford University Press, New York. 2nd ed.
16. de Gelder R., Heijnsdijk E.A., van Ravesteyn N.T., et al. Interpreting overdiagnosis estimates in population-based mammography screening. Epidemiol Rev 2011, 33:111-121.
17. Puliti D., Zappa M., Miccinesi G., et al. An estimate of overdiagnosis 15 years after the start of mammographic screening in Florence. Eur J Cancer 2009, 45:3166-3171.
18. Paci E., Miccinesi G., Puliti D., et al. Estimate of overdiagnosis of breast cancer due to mammography after adjustment for lead time. A Service Screening Study in Italy. Breast Cancer Res 2006, 8:R68.
19. Olsen A.H., Agbaje O.F., Myles J.P., et al. Overdiagnosis, sojourn time, and sensitivity in the Copenhagen mammography screening program. Breast J 2006, 12:338-342.
20. Waller M., Moss S., Watson J., et al. The effect of mammographic screening and hormone replacement therapy use on breast cancer incidence in England and Wales. Cancer Epidemiol Biomarkers Prev 2007, 16:2257-2261.
21. Duffy S.W., Tabar L., Olsen A.H., et al. Absolute numbers of lives saved and overdiagnosis in breast cancer screening from a randomized trial and from the Breast Cancer Screening Programme in England. J Med Screen 2010, 17:25-30.
22. SEER cancer statistics review 2013, National Cancer Institute, Bethesda, MD.
23. Gallager H.S., Martin J.E. Early phases in the development of breast cancer. Cancer 1969, 24:1170-1178.
24. Gallager H.S.W., Martin J.E. The study of mammary carcinoma by mammography and whole organ sectioning. Cancer 1969, 23:855-873.
25. Silverstein M. Non-invasive breast cancer: the dilemma of the 1990's. Obstet Gynecol Clin North Am 1994, 21:639-658.
26. Smart C.R., Byrne C., Smith R.A., et al. Twenty year follow-up of the breast cancers diagnosed during the Breast Cancer Detection Demonstration Project. CA Cancer J Clin 1997, 47:134-149.
27. Tabar L., Duffy S., Vitak B., et al. The natural history of breast cancer. What have we learned from screening?. Cancer 1999, 86:449-462.
28. Silverstein M.J., Poller D.N., Waisman J.R., et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet 1995, 345:1154-1157.
29. United Kingdom National Health Service. NHS Breast Screening Programme & Association of Breast Surgery at BASO: an audit of screen detected breast cancers for the year of screening April 2007 to March 2008. UK West Midlands Cancer Intelligence Unit; 2009.
30. Yen M.F., Tabar L., Smith R.A., et al. Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. Eur J Cancer 2003, 39:1746-1754.
31. McCann J., Treasure P., Duffy S.W. Modeling the impact of detecting and treating ductal carcinoma in situ in a breast screening programme. J Med Screen 2004, 11:117-125.
32. Chen H.H., Duffy S.W., Tabar L., et al. Markov chain models for progression of breast cancer. Part I: tumor attributes and the preclinical screen-detectable phase. J Epidemiol Biostat 1997, 2:9-23.
33. Carlson K.L., Helvie M.A., Roubidoux M.A., et al. Relationship between mammography screening intervals and size and histology of ductal carcinoma in situ. AJR Am J Roentgenol 1999, 172:313-317.
34. Feig S.A., Schwartz G.F., Nerlinger R., et al. Prognostic factors of breast neoplasms detected on screening by mammography and physical examination. Radiology 1979, 133:577-582.
35. Nielsen M., Jensen J., Andersen J. Precancerous and cancerous breast lesions during lifetime and at autopsy: a study of 83 women. Cancer 1984, 54:612-615.
36. Nielsen M., Thomsen J.L., Primdahl S., et al. Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. Br J Cancer 1987, 56:814-819.
37. Page D.L., Dupont W.D., Rogers L.W., et al. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer 1982, 49:751-758.
38. Page D.L., Dupont W.D., Rogers L.W., et al. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 1995, 76:1197-1200.
39. Rosen P.P., Braun D.W., Kinne D.E. The clinical significance of pre-invasive breast carcinomas. Cancer 1980, 46:919-925.
40. Betsill W., Rosen P.P., Lieberman P.M., et al. Intraductal carcinoma: long-term follow-up after biopsy along. JAMA 1978, 239:1863-1867.
41. Smith R.A., Saslow D., Sawyer K.A., et al. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin 2003, 53:141-169.
42. Masood S. Focusing on breast cancer overdiagnosis and overtreatment: the promise of molecular medicine. Breast J 2013, 19:127-129.
43. Colin C., Devonassoux-Shisheboran M., Sardanelli F. Is breast cancer overdiagnosis also nested in pathologic misclassification?. Radiology 2014, 273:652-655.
44. Katz S.J., Morrow M. Addressing overtreatment in breast cancer. Cancer 2013, 15:3584-3588.